Zealand Pharma and Generate Announce $1.2 Billion AI-Driven Drug Discovery Deal

Zealand Pharma and Generate have announced a collaboration valued at up to $1.2 billion to develop AI-designed multispecific protein therapeutics targeting obesity and other metabolic diseases.

The partnership highlights the growing role of artificial intelligence in biologics discovery, particularly in designing complex protein molecules with multiple biological activities. By combining computational protein design with pharmaceutical development expertise, the collaboration aims to accelerate the discovery of innovative therapeutic candidates for metabolic disorders.

AI-driven protein engineering is increasingly transforming drug discovery by enabling researchers to explore molecular designs, optimize protein properties, and investigate therapeutic approaches that may be difficult to achieve using conventional methods alone.

The agreement also reflects the pharmaceutical industry's growing investment in generative AI and computational biology, positioning engineered proteins as an important area of innovation in next-generation therapeutics.

For the peptide and protein science community, this development underscores the importance of integrating AI, protein engineering, and translational research to advance new therapeutic possibilities.

AI-Designed Proteins Could Make Cancer Treatments Safer and More Precise

Researchers at Dana-Farber Cancer Institute have developed an artificial intelligence-based approach to designing proteins that selectively bind to specific drug molecules. The method, known as neural iterative selection–expansion (NISE), uses computational modeling to generate and refine protein designs, potentially reducing the need for extensive experimental screening.

In a study published in 2026, the researchers designed proteins that bind to exatecan, a cancer drug used in antibody–drug conjugates, and apixaban, a blood thinner. This approach could pave the way for engineered proteins that protect drug molecules, improve targeted delivery, monitor drug levels, or help reduce unwanted side effects.

Although the technology remains at an early research stage, it highlights the growing potential of AI-driven protein engineering to advance precision medicine and next-generation therapeutics.